Regulatory changes
207 regulatory changes appeared in United States during Week 17, 2026. Regulatory-change activity should be checked against FDA requirements, guidance, and downstream compliance workflows.
United States medical device regulatory intelligence, Week 17, 2026.
Signals from 2026-04-20 to 2026-04-26, covering safety alerts, regulatory changes, device registrations, market movement, and source activity for United States.
Signals
326
Sources
8
Index status
Indexable
EXECUTIVE SUMMARY
United States generated 326 qualifying medical device signals during Week 17, 2026. Regulatory changes led the week with 207 signals, while FDA Device Registration & Listing was the most active source. Neuroscientists identify brain regions involved in replaying emotional memories during sleep, including the hippocampus and amygdala. Study finds toxins and climate change significantly reduce fertility across global species, including humans.
Key observations
Regulatory changes accounted for 207 of 326 qualifying signals, making it the main review lane for the week.
Safety alerts formed the second-largest cluster, which is useful context for teams separating safety work from regulatory and market monitoring.
FDA Device Registration & Listing contributed 206 signals, so source-level follow-up should start there.
Anson appeared repeatedly in the highlighted signals, which may warrant closer product, manufacturer, or competitor tracking.
Category interpretation
Safety alerts
100 safety alerts appeared in United States during Week 17, 2026. Safety concentration usually matters to quality, vigilance, and post-market surveillance teams because it can reveal emerging field risks.
Competitor launches
12 competitor launches appeared in United States during Week 17, 2026. Competitor-linked activity is most useful when paired with product codes, indication context, and adjacent safety signals.
Market signals
4 market signals appeared in United States during Week 17, 2026. Market signals help connect regulatory monitoring with launch planning, reimbursement, and commercial strategy.
Recommended monitoring focus
- Review FDA safety and recall activity for product categories that overlap your portfolio.
- Check whether new US regulatory changes affect submission, labeling, vigilance, or post-market workflows.
- Review competitor-linked signals for launch timing, market access movement, and product category momentum.
- Use market trend signals to brief commercial, strategy, and market access teams alongside regulatory stakeholders.
Source-backed signal evidence
These source-linked items support the weekly analysis above. They are included for verification and follow-up, not as a raw feed export.
Medical Xpress·Market signals·
How the brain replays past emotional experiences during sleep
Neuroscientists identify brain regions involved in replaying emotional memories during sleep, including the hippocampus and amygdala.
SourceThe Guardian Medical Research·Market signals·
Toxins plus climate harms likely cause of reduced fertility, study finds
Study finds toxins and climate change significantly reduce fertility across global species, including humans.
SourceThe Hindu Health·Industry events·
Experts discuss preventive care and data-led approach to public health challenges
Experts highlighted the role of AI in addressing public health challenges, including infectious diseases and NCDs.
SourceThe Guardian Healthcare·Industry events·
‘I picked up the bottle of Jacob’s Creek and drank straight out of it. I was seven’: John Robins on being an alcoholic
John Robins recalls his early experiences with alcohol, starting at age five, contrasting with his mother's sobriety.
SourceNikkei Asia·Market signals·
BYD earnings, Japanese airline financials, Genting's New York casino tables
BYD reports earnings, impacting the financial landscape in key markets including Asia Pacific.
SourceWashington Post Health·Market signals·
I study wearable health data. Here’s what continuous glucose monitors miss.
Continuous glucose monitors may cause confusion and anxiety without aiding health decisions, experts warn.
SourceGDELT Medical Device Monitor·Competitor launches·
FDA approves first gene therapy for inherited hearing loss
The FDA has approved the first gene therapy specifically for inherited hearing loss.
SourceGDELT Medical Device Monitor·Regulatory changes·
FDA moves to fast - track review of psychedelic drugs for mental health
FDA accelerates the review process for psychedelic drugs aimed at mental health treatments.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Impression tray by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co., Ltd. registered an impression tray as a Class I medical device in EUDAMED.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Edentulous Impression Trays by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co.,Ltd. registered Edentulous Impression Trays as Class I medical devices in EUDAMED.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Edentulous Impression Trays by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co., Ltd. registered Edentulous Impression Trays as Class I medical devices in EUDAMED.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Impression tray by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co., Ltd. has registered an impression tray classified as Class I medical device.
SourceRegulatory changes
GDELT Medical Device Monitor·Regulatory changes·
FDA moves to fast - track review of psychedelic drugs for mental health
FDA accelerates the review process for psychedelic drugs aimed at mental health treatments.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: Co-Innovation Biotech Co.,Ltd. (3010220539)
Co-Innovation Biotech Co., Ltd. has FDA registration 3010220539 for product code LCX.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: IntroMedic Co., Ltd. (3007244127)
IntroMedic Co., Ltd. has registered a medical device with the FDA under product code NEZ.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: JINHUA GLAMB MEDICAL EQUIPMENT CO.,LTD (3014737068)
JINHUA GLAMB MEDICAL EQUIPMENT CO.,LTD has registered product code DZD with the FDA.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: Clarius Mobile Health Corp. (3012747207)
Clarius Mobile Health Corp. has registered three products with the FDA under code IYO.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: CONFORTEX, S.A. (3001159036)
CONFORTEX, S.A. has registered a medical device with the FDA under product code FMP.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: Shenzhen Perfect Medical Instruments Co., Ltd. (3009431661)
Shenzhen Perfect Medical Instruments Co., Ltd. has registered with the FDA under product code EKN.
SourceFDA Device Registration & Listing·Regulatory changes·
FDA Registration: DongGuan Dawei Sanitary Products Co., Ltd. (3009511130)
DongGuan Dawei Sanitary Products Co., Ltd. has registered a product with FDA under code FRL.
SourceSafety alerts
FDA Warning Letters·Safety alerts·
FDA Class I: Expo 5F Selective Angiographic Catheters, MODEL - 5F EXPO AR1 (5PK), REF H74908526842; cardiac catheter (Boston Scientific Corporation)
Boston Scientific recalls Class I Expo 5F angiographic catheters due to guidewire advancement issues.
SourceFDA Warning Letters·Safety alerts·
FDA Class I: Vitek 2 Gram Positive Susceptibility Test Cards (AST-P640 REF 418579), 20 cards/kit. Product Usage: The VITEK 2 Gram Positive Susceptibility Card is intended for use with VITEK 2 Systems in cli (Biomerieux Inc)
The FDA issued a Class I recall for Vitek 2 Gram Positive Susceptibility Test Cards due to performance limitations.
SourceFDA Warning Letters·Safety alerts·
FDA Class I: UniCel DxH 800 Coulter Cellular Analysis System, REF numbers 629029, B24465, B24802, B68304, B66445, and B63322. Product Usage: The UniCel DxH 800 Analyzer is a quantitative multi-parameter, autom (Beckman Coulter Inc.)
The FDA has issued a Class I recall for the UniCel DxH 800 Analyzer due to erroneous platelet results.
SourceFDA Warning Letters·Safety alerts·
FDA Class I: MOVES System, an emergency ventilator with suction, oxygen concentrator and multi-parameter patient monitoring capabilities. The MOVES System is a portable computer controlled electrically powered (Thornhill Research Inc)
The FDA issued a Class I recall for the MOVES System due to unresponsive batteries affecting its operation.
SourceFDA Warning Letters·Safety alerts·
FDA Class I: Hudson RCI Sheridan EZ-ENDO: a) 5.0 mm, REF 5-22510 b) 5.5 mm, REF 5-22511 c) 7.0 mm, REF 5-22514 d) 7.5 mm, REF 5-22515 e) 8.0 mm, REF 5-22516 f) 8.5 mm, REF 5-22517 g) 9.0 mm, REF 5-22518 h) (Teleflex Medical)
FDA issued a Class I recall for Teleflex Medical's Sheridan EZ-ENDO due to disconnection risks in tracheal tubes.
SourceFDA Warning Letters·Safety alerts·
FDA Class I: Edwards Lifesciences Swan Ganz Thermodilution Catheter, REF 131F7P (5 pack of 131F7) Product Usage: The Swan-Ganz Thermodilution Catheter provides a diagnostic tool for physicians to rapidly determin (Edwards Lifesciences, LLC)
Edwards Lifesciences recalls Swan Ganz Thermodilution Catheters due to incorrect lumen assembly affecting pressure readings.
SourceFDA Warning Letters·Safety alerts·
FDA Class I: SHERPA NX ACTIVE GUIDING CATHETER, 6F AL2.0, .070", REF SA6AL20. for cardiovascular use (Medtronic Vascular)
Medtronic Vascular recalls SHERPA NX ACTIVE GUIDING CATHETER due to potential material loss affecting safety.
SourceFDA Warning Letters·Safety alerts·
FDA Class I: Lotus Edge Valve System, Transcatheter Aortic Valve Prosthesis Premounted on Delivery System, 23mm, sterile, REF H749LVSUS230, GTIN 08714729960904 (Boston Scientific Corporation)
FDA issued a Class I recall for the Lotus Edge Valve System due to inspection failures during deployment.
SourceCompetitor launches
GDELT Medical Device Monitor·Competitor launches·
FDA approves first gene therapy for inherited hearing loss
The FDA has approved the first gene therapy specifically for inherited hearing loss.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Impression tray by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co., Ltd. registered an impression tray as a Class I medical device in EUDAMED.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Edentulous Impression Trays by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co.,Ltd. registered Edentulous Impression Trays as Class I medical devices in EUDAMED.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Edentulous Impression Trays by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co., Ltd. registered Edentulous Impression Trays as Class I medical devices in EUDAMED.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Impression tray by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co., Ltd. has registered an impression tray classified as Class I medical device.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Implant Tray by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co.,Ltd. registered an Implant Tray classified as Class I in EUDAMED.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Impression tray by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co., Ltd. registered an impression tray classified as Class I medical device.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Implant Tray by Anson Investment Development Co.,Ltd. (Class refdata.risk-class.class-i)
Anson Investment Development Co.,Ltd. registered an Implant Tray classified as Class I in EUDAMED.
SourceMarket signals
Medical Xpress·Market signals·
How the brain replays past emotional experiences during sleep
Neuroscientists identify brain regions involved in replaying emotional memories during sleep, including the hippocampus and amygdala.
SourceThe Guardian Medical Research·Market signals·
Toxins plus climate harms likely cause of reduced fertility, study finds
Study finds toxins and climate change significantly reduce fertility across global species, including humans.
SourceNikkei Asia·Market signals·
BYD earnings, Japanese airline financials, Genting's New York casino tables
BYD reports earnings, impacting the financial landscape in key markets including Asia Pacific.
SourceWashington Post Health·Market signals·
I study wearable health data. Here’s what continuous glucose monitors miss.
Continuous glucose monitors may cause confusion and anxiety without aiding health decisions, experts warn.
SourceIndustry events
The Hindu Health·Industry events·
Experts discuss preventive care and data-led approach to public health challenges
Experts highlighted the role of AI in addressing public health challenges, including infectious diseases and NCDs.
SourceThe Guardian Healthcare·Industry events·
‘I picked up the bottle of Jacob’s Creek and drank straight out of it. I was seven’: John Robins on being an alcoholic
John Robins recalls his early experiences with alcohol, starting at age five, contrasting with his mother's sobriety.
SourceCompetitor moves
Fortune Health·Competitor moves·
SpaceX, Anduril among companies to win Golden Dome contracts
The US Space Force awarded contracts worth $3.2 billion to 12 companies, including SpaceX, for space-based interceptors.
SourceTrack these signals continuously.
MedFlux monitors regulators and medical device market sources across priority countries so regulatory, quality, and strategy teams can review changes without manually checking agency databases.